1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Roche Acquires 89bio

M&A Deal Summary

Roche Acquires 89bio

On September 17, 2025, Roche acquired life science company 89bio for 2.4B USD

Acquisition Highlights
  • This is Roche’s 31st transaction in the Life Science sector.
  • This is Roche’s 8th largest (disclosed) transaction.
  • This is Roche’s 30th transaction in the United States.
  • This is Roche’s 16th transaction in California.

M&A Deal Summary
Date 2025-09-17
Target 89bio
Sector Life Science
Buyer(s) Roche
Deal Type Add-on Acquisition
Deal Value 2.4B USD
Advisor(s) Moelis & Co.
Centerview Partners (Financial)
Gibson, Dunn & Crutcher (Legal)

Target

89bio

San Francisco, California, United States
89bio operates as a biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. 89bio was formed in 2018 and is based in San Francisco, California.

Search 215,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Roche

Basel, Switzerland
Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 62.4B CHF (2024)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. It offers diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.

DEAL STATS #
Overall 44 of 44
Sector: Life Science M&A 31 of 31
Type: Add-on Acquisition M&A Deals 36 of 36
State: California M&A 16 of 16
Country: United States M&A 30 of 30
Year: 2025 M&A 1 of 1
Size (of disclosed) 8 of 31
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-11-26 Poseida Therapeutics

San Diego, California, United States

Poseida Therapeutics is a therapeutics-focused biotechnology company using best-in-class genome engineering technologies to develop novel, life-saving treatments, including gene therapies for orphan liver diseases and immuno-oncology therapeutics for several types of cancer. Poseida Therapeutics was founded in 2014 and is based in San Diego, California.

Buy $1.0B
Mergr

Solution for

Product

Company

Legal